SlideShare a Scribd company logo
1 of 30
Download to read offline
By….
E. MADHAN MOHAN
Asso. Professor
Department of Pharmacology
1
1. INTRODUCTION
2. FUNCTIONS
3. CONCEPT OF TDM
4. WHEN & WHY TDM IS REQUIRED?
5. DO ALL DRUGS NEED TDM?
6. COMMONLY MONITORED DRUGS
7. ANALYTICAL METHODOLOGY OF TDM
8. BENEFITS OF TDM
9. SERVICES OF TDM
10. CONCLUSION
11. REFERENCES
2
DEFINITION
Therapeutic drug monitoring refers to the
individualization of dosage by
maintaining plasma or blood drug
concentrations within a target range
(Therapeutic range, therapeutic window).
It manages the drug therapy in individual
patient often requires evaluation of
response of the patient to the
recommended dosage.
3
DURATION OF ACTION
TOXIC
LEVEL
THERAPEUTIC RANGE
ABSORPTIONPHASE
ELIMINATIONPHASE
 Select drug
 Design dosage regimen
 Evaluate patient response
 Determine need for measuring serum concentration
 Assay for drug concentration in biological fluids
 Perform pharmacokinetic evaluation of drug
concentration
 Re-adjust the dosage regimen
5
 TDM is based on the principle that for some drugs there is
close relationship between the plasma level of the drug and its
clinical effect.
 The main aim of therapeutic drug monitoring is to find out an
effective medication against the disease without any dangerous
toxic action.
 The purpose of TDM is to individualize the dosage to achieve
maximum efficacy of a drug and at the same time minimize
adverse drug reactions.
6
7
 The drug has a narrow therapeutic index
A direct relation exists between the drug or
metabolite levels in plasma and the
pharmacological or toxic effects.
8
 The pharmacological effects can be clinically
quantified.
 When concentration effect relationship remains
unestablished.
 Drugs with wide therapeutic range such as beta
blockers and calcium channel blockers.
 Dosage need not be individualized.
9
 To achieve optimal drug therapy.
 To achieve desired pharmacological effect of a drug within
shortest possible time with no toxicity
 To benefit the patient medically and economically by
reducing hospital stay and drug related toxicity.
 To monitor individual complicating factors like patient
characteristics, diseases and drug interactions.
10
Drugs that do not need TDM:
 Drugs that used for treating diseases of which their
clinical end points can easily be monitored, e.g., BP,
HR, cardiac rhythm, blood sugar, blood cholesterol
and triglycerides, urine volume, body temperature,
inflammation, pain, headache, etc.
 Drugs with less complicated pharmacokinetics.
 Drugs that used to treat less complicated or not life
threatening diseases
11
1. Bronchodilators – Theophyllline
2. Antibiotics – Aminoglycosides (Gentamicin), Vancomycin
3. Immunosuppressant's – Cyclosporine, Tacrolimus and Sirolimus.
4. Antiepileptic –Phenytoin, valproic acid, carbamazepine,
ethosuximide, gabapentin, lamotrigine.
5. Cardiac drugs – Digoxin, digitoxin, quinidine, procainamide, N-
acetyl-procainamide
6. Psychoactive drugs – Lithium, valproic acid, some antidepressants
(imipramine, amitriptyline, nortriptyline, doxepin, desipramine)
7. Anti-cancer drugs- Methotrexate
8. Protease inhibitors- Indinavir, ritonavir, lopinavir, saquinavir,
atazanavir, nelfinavir
12
 Theophiline – It is a weak Bronchodilator. It acts with beta-
adrenergic. It has a very narrow therapeutic range 10-
20mcg/ml. At the high concentrations toxicity is severe.
 Aminoglycosides – These are more active at alkaline ph
than at acidic ph, and are ototoxic and nephrotoxic. It has a
narrow therapeutic range of 5-10mcg/ml(peak)
<2mcg/ml(trough)
 Digoxin – It has a very low therapeutic index. Samples are
taken at least 6 h post-dose to ensure that distribution of
digoxin. Its therapeutic range is 0.5-2mcg/ml.
13
 Lithium – if TDM have more adverse effects, lithium
levels were above therapeutic range (>1.2mmol/l)sub
therapeutic range (<0.6mmol/l)with in therapeutic
range (0.6mmol/l) lithium levels monitoring helps in
poor compliance and for better clinical management.
 Phenytoin –It has a low therapeutic index and exhibits
saturation kinetics (i.e. increases in small dose results
in increases in large concentration).
14
15
The fundamental procedures necessary for the quantification of the drug in
the body are: recovery from body fluids, tissues, and organs, separation
from the biological components, identification of the species concerned
and finally quantification.
The analytical methodology employed should ideally
 Distinguish between compounds of similar structure – unchanged drug
and metabolites.
 Detect small amounts.
 Be simple enough to use as a routine assay and
 Be unaffected by other drugs administered simultaneously.
16
 Prior to advent of GLC and HPLC, drug samples were
analyzed by spectrophotometric methods.
 Solvent extraction schemes coupled with a
spectrophotometric finish can still provide a much derived
simplicity in assay procedure when the level of sensitivity
required is not too low. i.e., in the µg/ml range.
However the drawbacks are
 large volume of samples,
 complex extraction procedures ,
 interference by other compounds.
17
TLC possesses adequate resolutions for identifying many drugs
but it suffers from inability to quantify these drugs accurately
and time consuming technique with inadequate sensitivity.
However it is a useful technique in toxicology laboratory.
HPLC and GLC
These methods are highly specific, precise and sensitive. Besides
multiple analyses can be done.
18
 It is sensitive, reasonably precise but requires the use of
radionuclide. Cross reactivity with other closely reacted drugs
is a potential problem with this technique. The hazard of using
radioactive material is a considerable limitation of this method.
EnzymE ImmunE assay
 These techniques offer some advantages over RIA in
that no radioactive tracer is required, there is no need to
separate the bound from the unbound fractions.
However the potential for cross reactivity still exits.
19
a) Phenytoin: Since phenytoin has a long half life a single daily
dose may be employed and so the timing of concentration
monitoring is not critical.
b) Lithium: A 12 hr sample gives the most precise guide to
dosage adjustment.
c) Digoxin: The measurement must be made at least six hours
after a dose to avoid inappropriate high levels.
d) Theophylline: This drug has a narrow therapeutic index and
timing of sampling is not critical if the patient is receiving one
of the slow release formulations.
20
 Blood specimen should not be taken until steady-state
has been achieved. This applies to changes in dosages
as well as following the initiation of therapy.
21
DRUG MINIMUM
PLASMA/S
ERUM
VOLUME
(ml)
APPROXIM
ATE TIME
TO
STEADY
STATE
(DAYS)
RECOMME
NDED
SAMPLING
TIME
TARGET
RANGE
Digoxin 0.5 5-7 6-24 h
post-dose
0.8-2.0
�g/L
Phenytoin 0.5 7-35 pre-dose* 10-20 mg/L
Theophyllin
e - adults
(1)
0.5 2 2-4 h post-
dose
10-20 mg/L
Theophyllin
e -
neonates
0.5 2 2-4 h post-
dose
5-10 mg/L
22
 Patient Name............................................. Date...............................................
HN........................................................
Age.................................. Sex................................. Wt...................................... Ht...................
......................................
Ward.............................................Ordered by....................................................... Phone N
o..........................................
DRUG LEVEL REQUESTED........................................................................................................
..........................................
REASON FOR REQUEST :
( ) Suspected toxicity ( ) Compliance
( ) Therapeutic confirmation ( ) Absence of therapeutic response
Please indicate when level is needed :
( ) within 24 h ( ) within 1-2 h
( ) stat ( ) others........................
TIME AND DATE OF LAST DOSE :
Date.................... Route : IV, IM, SC, PO, Others...........................
Time.................... Dose.......................... Freq..................................
THIS DRUG LEVEL IS FOR : SAMPLING TIME :
( ) Trough or predose level
Date....................... Time.........................
( ) Peak level Date....................... Time.......................
.
DOES THE PATIENT HAVE ORGAN-SYSTEM DAMAGE ?
( ) Renal ( ) Hepatic ( ) Cardiac ( ) GI ( ) End
ocrine ( ) Others........................….
OTHER DRUG(S) PATIENT IS TAKING :..............................................................................
...........................…….. 23
HOsPITaL
Reduce hospital congestion
Increase quality of Rx and service
Economic consideration
Personnel: research, promotion & self esteem
Medico-legal aspects
24
 PATIENT CARE
Decrease duration of stay in hospital
Receive safer and more effective Rx
Increased productivity
Improve quality of life
25
 Hospital personnel do not know the TDM
service
 Physicians do not understand the principles,
benefits, and the limitations of TDM service
 Inappropriate sampling times
 Insufficient patient’s history and other
necessary data
 No consultation when problems arise
26
 The Laboratory currently offers a routine service for the measurement of
the following drugs in plasma:-Emergency within-hours services are
available for TDM provided that there is sufficient clinical justification for
the request.
 The Laboratory can usually provide a result within 30 minutes of receipt of
the specimen.
 Twice Daily Service Monday - Friday
Anticonvulsant drugs: Carbamazepine, Ethosuximide, Phenytoin,
Phenobarbitone, Valproic acid.Cardioactive drug: Digoxin. Respiratory
stimulants: Caffeine, Theophylline
 Twice Weekly Service
Gabapentin, Lamotrigine, Vigabatrin.
 Weekly Service
Tricycle antidepressants: Amitriptyline, Clomipramine, Desipramine,
Imipramine, Nortriptyline.
27
 The appropriate use of TDM ultimately leads to
effective patient care management. It decreases the
side effects, reduces the toxicity and drug
interactions.
Thus TDM is reliable, valuable and efficient of
patient compliance and management of therapy in
patients receiving medication or suffering from
other diseases.
28
 Therapeutic drug monitoring- chapter-7 concepts,
methodology, clinical applications and limitations C.
Suthakaran and C.Adithan
 G.Parthasarathi,Karin nyfort-Hansen.Therapeutic drug
monitoring.In:A Text Book of Clinical Pharmacy
Practise.Universities Press,Mysore,2007,pp.325-343.
 D.M.Brahmankar,Sunil B.Jaiswal.Monitoring Drug
Therapy.In:Biopharmaceutics and pharmacokinetics A
Treatise,Vallabh prakashan,New Delhi,2008,pp.320-321.
 www.toxlab.co.uk/tdm.htm - Cached
29
30

More Related Content

What's hot

Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug MonitoringTulasi Raman
 
Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]BADAR UDDIN UMAR
 
Therapeutic Drug Monitoring
 Therapeutic Drug Monitoring Therapeutic Drug Monitoring
Therapeutic Drug MonitoringRajat Mahamana
 
Therapeutic drug monitoring ppt
Therapeutic drug monitoring pptTherapeutic drug monitoring ppt
Therapeutic drug monitoring pptPARUL UNIVERSITY
 
Medication history interview
Medication history interviewMedication history interview
Medication history interviewRafi Bhat
 
Adverse Drug Reactions
Adverse Drug ReactionsAdverse Drug Reactions
Adverse Drug ReactionsKajal Rajdev
 
Pharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacistPharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacistDr. Ramesh Bhandari
 
Introduction to Clinical trial
Introduction to Clinical trial Introduction to Clinical trial
Introduction to Clinical trial rx_sonali
 
Patients medication history interview
Patients medication history interviewPatients medication history interview
Patients medication history interviewSubhash Yende
 
Pharmacovigilance program of India (PvPI)
Pharmacovigilance program of India (PvPI)Pharmacovigilance program of India (PvPI)
Pharmacovigilance program of India (PvPI)SnehaKhandale1
 
Community Pharmacy Management
Community Pharmacy ManagementCommunity Pharmacy Management
Community Pharmacy ManagementSubhash Yende
 
Rational use of otc medication
Rational use of otc medicationRational use of otc medication
Rational use of otc medicationRafi Bhat
 
Clinical pharmacy services
Clinical pharmacy servicesClinical pharmacy services
Clinical pharmacy servicesRafi Bhat
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoringsunayanamali
 
Causality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilanceCausality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilanceGaurav Chhabra
 

What's hot (20)

Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Drug Information Services
Drug Information ServicesDrug Information Services
Drug Information Services
 
Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]Clinical Pharmacokinetics-II [dosing of drugs, tdm]
Clinical Pharmacokinetics-II [dosing of drugs, tdm]
 
Therapeutic Drug Monitoring
 Therapeutic Drug Monitoring Therapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
Therapeutic drug monitoring ppt
Therapeutic drug monitoring pptTherapeutic drug monitoring ppt
Therapeutic drug monitoring ppt
 
Drug Therapy Monitoring
Drug Therapy MonitoringDrug Therapy Monitoring
Drug Therapy Monitoring
 
Bioavailability testing protocol
Bioavailability testing protocolBioavailability testing protocol
Bioavailability testing protocol
 
Medication history interview
Medication history interviewMedication history interview
Medication history interview
 
Adverse Drug Reactions
Adverse Drug ReactionsAdverse Drug Reactions
Adverse Drug Reactions
 
Pharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacistPharmacovigilance and role of pharmacist
Pharmacovigilance and role of pharmacist
 
Introduction to Clinical trial
Introduction to Clinical trial Introduction to Clinical trial
Introduction to Clinical trial
 
Patients medication history interview
Patients medication history interviewPatients medication history interview
Patients medication history interview
 
Pharmacovigilance program of India (PvPI)
Pharmacovigilance program of India (PvPI)Pharmacovigilance program of India (PvPI)
Pharmacovigilance program of India (PvPI)
 
Community Pharmacy Management
Community Pharmacy ManagementCommunity Pharmacy Management
Community Pharmacy Management
 
Rational use of otc medication
Rational use of otc medicationRational use of otc medication
Rational use of otc medication
 
Clinical pharmacy services
Clinical pharmacy servicesClinical pharmacy services
Clinical pharmacy services
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Causality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilanceCausality assessment,methods,pharmacovigilance
Causality assessment,methods,pharmacovigilance
 
Designing of dosage regimen
Designing of dosage regimenDesigning of dosage regimen
Designing of dosage regimen
 

Similar to Therapeutic Drug Monitoring (TDM)

Therapeutic drug monitoring final
Therapeutic drug monitoring finalTherapeutic drug monitoring final
Therapeutic drug monitoring finalsaiesh_phaldesai
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug MonitoringAhlam Sundus
 
Therapeutic drug monitoring PHARMACY sAA.ppt
Therapeutic drug monitoring PHARMACY sAA.pptTherapeutic drug monitoring PHARMACY sAA.ppt
Therapeutic drug monitoring PHARMACY sAA.pptssuser497f37
 
Therapeutic drug monitoring
Therapeutic  drug monitoringTherapeutic  drug monitoring
Therapeutic drug monitoringDr Sajeena Jose
 
THERAPEUTIC DRUG MONITORING S KOSEY
THERAPEUTIC DRUG MONITORING S KOSEYTHERAPEUTIC DRUG MONITORING S KOSEY
THERAPEUTIC DRUG MONITORING S KOSEYsopi_1234
 
Basic principles of tdm ali et al
Basic principles of tdm ali et alBasic principles of tdm ali et al
Basic principles of tdm ali et alAhmed Ali
 
Understanding Therapeutic drug monitoring (TDM) at a glance
Understanding Therapeutic drug monitoring (TDM) at a glanceUnderstanding Therapeutic drug monitoring (TDM) at a glance
Understanding Therapeutic drug monitoring (TDM) at a glanceAI Publications
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoringHarshita Jain
 
THERAPEUTIC DRUG MONITORING S KOSEY 2
THERAPEUTIC DRUG MONITORING S KOSEY 2THERAPEUTIC DRUG MONITORING S KOSEY 2
THERAPEUTIC DRUG MONITORING S KOSEY 2sopi_1234
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoringNaser Tadvi
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoringlavanya nalluri
 
TDM of drugs used in organ transplantation-detailed study
TDM of drugs used in organ transplantation-detailed studyTDM of drugs used in organ transplantation-detailed study
TDM of drugs used in organ transplantation-detailed studymartinshaji
 
General Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoringGeneral Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoringDr. Ramesh Bhandari
 
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...Shaikh Abusufyan
 
Therapeutic Drug Monitoring- Ravinandan A P
Therapeutic Drug Monitoring- Ravinandan A PTherapeutic Drug Monitoring- Ravinandan A P
Therapeutic Drug Monitoring- Ravinandan A PRavinandan A P
 
Therapeutic drug monitoring- Descriptive questions and answers.docx
Therapeutic drug monitoring- Descriptive questions and answers.docxTherapeutic drug monitoring- Descriptive questions and answers.docx
Therapeutic drug monitoring- Descriptive questions and answers.docxDipeshGamare
 

Similar to Therapeutic Drug Monitoring (TDM) (20)

Therapeutic drug monitoring final
Therapeutic drug monitoring finalTherapeutic drug monitoring final
Therapeutic drug monitoring final
 
Therapeutic Drug Monitoring
Therapeutic Drug MonitoringTherapeutic Drug Monitoring
Therapeutic Drug Monitoring
 
Therapeutic drug monitoring PHARMACY sAA.ppt
Therapeutic drug monitoring PHARMACY sAA.pptTherapeutic drug monitoring PHARMACY sAA.ppt
Therapeutic drug monitoring PHARMACY sAA.ppt
 
TDM Group 06.pptx
TDM Group 06.pptxTDM Group 06.pptx
TDM Group 06.pptx
 
Therapeutic drug monitoring
Therapeutic  drug monitoringTherapeutic  drug monitoring
Therapeutic drug monitoring
 
THERAPEUTIC DRUG MONITORING S KOSEY
THERAPEUTIC DRUG MONITORING S KOSEYTHERAPEUTIC DRUG MONITORING S KOSEY
THERAPEUTIC DRUG MONITORING S KOSEY
 
Basic principles of tdm ali et al
Basic principles of tdm ali et alBasic principles of tdm ali et al
Basic principles of tdm ali et al
 
Understanding Therapeutic drug monitoring (TDM) at a glance
Understanding Therapeutic drug monitoring (TDM) at a glanceUnderstanding Therapeutic drug monitoring (TDM) at a glance
Understanding Therapeutic drug monitoring (TDM) at a glance
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
THERAPEUTIC DRUG MONITORING S KOSEY 2
THERAPEUTIC DRUG MONITORING S KOSEY 2THERAPEUTIC DRUG MONITORING S KOSEY 2
THERAPEUTIC DRUG MONITORING S KOSEY 2
 
Ppt tdm new
Ppt tdm newPpt tdm new
Ppt tdm new
 
TDM.pptx
TDM.pptxTDM.pptx
TDM.pptx
 
TDM.pptx
TDM.pptxTDM.pptx
TDM.pptx
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
Therapeutic drug monitoring
Therapeutic drug monitoringTherapeutic drug monitoring
Therapeutic drug monitoring
 
TDM of drugs used in organ transplantation-detailed study
TDM of drugs used in organ transplantation-detailed studyTDM of drugs used in organ transplantation-detailed study
TDM of drugs used in organ transplantation-detailed study
 
General Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoringGeneral Introduction on therapeutic drug monitoring
General Introduction on therapeutic drug monitoring
 
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
Therapeutic Drug Monitoring (TDM) | Criteria and Indications of TDM | Why TDM...
 
Therapeutic Drug Monitoring- Ravinandan A P
Therapeutic Drug Monitoring- Ravinandan A PTherapeutic Drug Monitoring- Ravinandan A P
Therapeutic Drug Monitoring- Ravinandan A P
 
Therapeutic drug monitoring- Descriptive questions and answers.docx
Therapeutic drug monitoring- Descriptive questions and answers.docxTherapeutic drug monitoring- Descriptive questions and answers.docx
Therapeutic drug monitoring- Descriptive questions and answers.docx
 

Recently uploaded

Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsEmily Kunka, MS, CCRP
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)1922Jaygohel
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)MedicoseAcademics
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfrg0000009
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 

Recently uploaded (20)

Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient Insights
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)Transport across cell membrane (passive, active, vesicular)
Transport across cell membrane (passive, active, vesicular)
 
Cure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdfCure of patients which terminally ill.pdf
Cure of patients which terminally ill.pdf
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 

Therapeutic Drug Monitoring (TDM)

  • 1. By…. E. MADHAN MOHAN Asso. Professor Department of Pharmacology 1
  • 2. 1. INTRODUCTION 2. FUNCTIONS 3. CONCEPT OF TDM 4. WHEN & WHY TDM IS REQUIRED? 5. DO ALL DRUGS NEED TDM? 6. COMMONLY MONITORED DRUGS 7. ANALYTICAL METHODOLOGY OF TDM 8. BENEFITS OF TDM 9. SERVICES OF TDM 10. CONCLUSION 11. REFERENCES 2
  • 3. DEFINITION Therapeutic drug monitoring refers to the individualization of dosage by maintaining plasma or blood drug concentrations within a target range (Therapeutic range, therapeutic window). It manages the drug therapy in individual patient often requires evaluation of response of the patient to the recommended dosage. 3
  • 4. DURATION OF ACTION TOXIC LEVEL THERAPEUTIC RANGE ABSORPTIONPHASE ELIMINATIONPHASE
  • 5.  Select drug  Design dosage regimen  Evaluate patient response  Determine need for measuring serum concentration  Assay for drug concentration in biological fluids  Perform pharmacokinetic evaluation of drug concentration  Re-adjust the dosage regimen 5
  • 6.  TDM is based on the principle that for some drugs there is close relationship between the plasma level of the drug and its clinical effect.  The main aim of therapeutic drug monitoring is to find out an effective medication against the disease without any dangerous toxic action.  The purpose of TDM is to individualize the dosage to achieve maximum efficacy of a drug and at the same time minimize adverse drug reactions. 6
  • 7. 7
  • 8.  The drug has a narrow therapeutic index A direct relation exists between the drug or metabolite levels in plasma and the pharmacological or toxic effects. 8
  • 9.  The pharmacological effects can be clinically quantified.  When concentration effect relationship remains unestablished.  Drugs with wide therapeutic range such as beta blockers and calcium channel blockers.  Dosage need not be individualized. 9
  • 10.  To achieve optimal drug therapy.  To achieve desired pharmacological effect of a drug within shortest possible time with no toxicity  To benefit the patient medically and economically by reducing hospital stay and drug related toxicity.  To monitor individual complicating factors like patient characteristics, diseases and drug interactions. 10
  • 11. Drugs that do not need TDM:  Drugs that used for treating diseases of which their clinical end points can easily be monitored, e.g., BP, HR, cardiac rhythm, blood sugar, blood cholesterol and triglycerides, urine volume, body temperature, inflammation, pain, headache, etc.  Drugs with less complicated pharmacokinetics.  Drugs that used to treat less complicated or not life threatening diseases 11
  • 12. 1. Bronchodilators – Theophyllline 2. Antibiotics – Aminoglycosides (Gentamicin), Vancomycin 3. Immunosuppressant's – Cyclosporine, Tacrolimus and Sirolimus. 4. Antiepileptic –Phenytoin, valproic acid, carbamazepine, ethosuximide, gabapentin, lamotrigine. 5. Cardiac drugs – Digoxin, digitoxin, quinidine, procainamide, N- acetyl-procainamide 6. Psychoactive drugs – Lithium, valproic acid, some antidepressants (imipramine, amitriptyline, nortriptyline, doxepin, desipramine) 7. Anti-cancer drugs- Methotrexate 8. Protease inhibitors- Indinavir, ritonavir, lopinavir, saquinavir, atazanavir, nelfinavir 12
  • 13.  Theophiline – It is a weak Bronchodilator. It acts with beta- adrenergic. It has a very narrow therapeutic range 10- 20mcg/ml. At the high concentrations toxicity is severe.  Aminoglycosides – These are more active at alkaline ph than at acidic ph, and are ototoxic and nephrotoxic. It has a narrow therapeutic range of 5-10mcg/ml(peak) <2mcg/ml(trough)  Digoxin – It has a very low therapeutic index. Samples are taken at least 6 h post-dose to ensure that distribution of digoxin. Its therapeutic range is 0.5-2mcg/ml. 13
  • 14.  Lithium – if TDM have more adverse effects, lithium levels were above therapeutic range (>1.2mmol/l)sub therapeutic range (<0.6mmol/l)with in therapeutic range (0.6mmol/l) lithium levels monitoring helps in poor compliance and for better clinical management.  Phenytoin –It has a low therapeutic index and exhibits saturation kinetics (i.e. increases in small dose results in increases in large concentration). 14
  • 15. 15
  • 16. The fundamental procedures necessary for the quantification of the drug in the body are: recovery from body fluids, tissues, and organs, separation from the biological components, identification of the species concerned and finally quantification. The analytical methodology employed should ideally  Distinguish between compounds of similar structure – unchanged drug and metabolites.  Detect small amounts.  Be simple enough to use as a routine assay and  Be unaffected by other drugs administered simultaneously. 16
  • 17.  Prior to advent of GLC and HPLC, drug samples were analyzed by spectrophotometric methods.  Solvent extraction schemes coupled with a spectrophotometric finish can still provide a much derived simplicity in assay procedure when the level of sensitivity required is not too low. i.e., in the µg/ml range. However the drawbacks are  large volume of samples,  complex extraction procedures ,  interference by other compounds. 17
  • 18. TLC possesses adequate resolutions for identifying many drugs but it suffers from inability to quantify these drugs accurately and time consuming technique with inadequate sensitivity. However it is a useful technique in toxicology laboratory. HPLC and GLC These methods are highly specific, precise and sensitive. Besides multiple analyses can be done. 18
  • 19.  It is sensitive, reasonably precise but requires the use of radionuclide. Cross reactivity with other closely reacted drugs is a potential problem with this technique. The hazard of using radioactive material is a considerable limitation of this method. EnzymE ImmunE assay  These techniques offer some advantages over RIA in that no radioactive tracer is required, there is no need to separate the bound from the unbound fractions. However the potential for cross reactivity still exits. 19
  • 20. a) Phenytoin: Since phenytoin has a long half life a single daily dose may be employed and so the timing of concentration monitoring is not critical. b) Lithium: A 12 hr sample gives the most precise guide to dosage adjustment. c) Digoxin: The measurement must be made at least six hours after a dose to avoid inappropriate high levels. d) Theophylline: This drug has a narrow therapeutic index and timing of sampling is not critical if the patient is receiving one of the slow release formulations. 20
  • 21.  Blood specimen should not be taken until steady-state has been achieved. This applies to changes in dosages as well as following the initiation of therapy. 21
  • 22. DRUG MINIMUM PLASMA/S ERUM VOLUME (ml) APPROXIM ATE TIME TO STEADY STATE (DAYS) RECOMME NDED SAMPLING TIME TARGET RANGE Digoxin 0.5 5-7 6-24 h post-dose 0.8-2.0 �g/L Phenytoin 0.5 7-35 pre-dose* 10-20 mg/L Theophyllin e - adults (1) 0.5 2 2-4 h post- dose 10-20 mg/L Theophyllin e - neonates 0.5 2 2-4 h post- dose 5-10 mg/L 22
  • 23.  Patient Name............................................. Date............................................... HN........................................................ Age.................................. Sex................................. Wt...................................... Ht................... ...................................... Ward.............................................Ordered by....................................................... Phone N o.......................................... DRUG LEVEL REQUESTED........................................................................................................ .......................................... REASON FOR REQUEST : ( ) Suspected toxicity ( ) Compliance ( ) Therapeutic confirmation ( ) Absence of therapeutic response Please indicate when level is needed : ( ) within 24 h ( ) within 1-2 h ( ) stat ( ) others........................ TIME AND DATE OF LAST DOSE : Date.................... Route : IV, IM, SC, PO, Others........................... Time.................... Dose.......................... Freq.................................. THIS DRUG LEVEL IS FOR : SAMPLING TIME : ( ) Trough or predose level Date....................... Time......................... ( ) Peak level Date....................... Time....................... . DOES THE PATIENT HAVE ORGAN-SYSTEM DAMAGE ? ( ) Renal ( ) Hepatic ( ) Cardiac ( ) GI ( ) End ocrine ( ) Others........................…. OTHER DRUG(S) PATIENT IS TAKING :.............................................................................. ...........................…….. 23
  • 24. HOsPITaL Reduce hospital congestion Increase quality of Rx and service Economic consideration Personnel: research, promotion & self esteem Medico-legal aspects 24
  • 25.  PATIENT CARE Decrease duration of stay in hospital Receive safer and more effective Rx Increased productivity Improve quality of life 25
  • 26.  Hospital personnel do not know the TDM service  Physicians do not understand the principles, benefits, and the limitations of TDM service  Inappropriate sampling times  Insufficient patient’s history and other necessary data  No consultation when problems arise 26
  • 27.  The Laboratory currently offers a routine service for the measurement of the following drugs in plasma:-Emergency within-hours services are available for TDM provided that there is sufficient clinical justification for the request.  The Laboratory can usually provide a result within 30 minutes of receipt of the specimen.  Twice Daily Service Monday - Friday Anticonvulsant drugs: Carbamazepine, Ethosuximide, Phenytoin, Phenobarbitone, Valproic acid.Cardioactive drug: Digoxin. Respiratory stimulants: Caffeine, Theophylline  Twice Weekly Service Gabapentin, Lamotrigine, Vigabatrin.  Weekly Service Tricycle antidepressants: Amitriptyline, Clomipramine, Desipramine, Imipramine, Nortriptyline. 27
  • 28.  The appropriate use of TDM ultimately leads to effective patient care management. It decreases the side effects, reduces the toxicity and drug interactions. Thus TDM is reliable, valuable and efficient of patient compliance and management of therapy in patients receiving medication or suffering from other diseases. 28
  • 29.  Therapeutic drug monitoring- chapter-7 concepts, methodology, clinical applications and limitations C. Suthakaran and C.Adithan  G.Parthasarathi,Karin nyfort-Hansen.Therapeutic drug monitoring.In:A Text Book of Clinical Pharmacy Practise.Universities Press,Mysore,2007,pp.325-343.  D.M.Brahmankar,Sunil B.Jaiswal.Monitoring Drug Therapy.In:Biopharmaceutics and pharmacokinetics A Treatise,Vallabh prakashan,New Delhi,2008,pp.320-321.  www.toxlab.co.uk/tdm.htm - Cached 29
  • 30. 30